Voltaren (diclofenac sodium enteric-coated tablets) and Voltaren-XR (diclofenac sodium extended-release) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2011

PRECAUTIONS

Drug Interactions
  • CYP2C9 Inhibitors or Inducers: Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. Use caution when dosing diclofenac with CYP2C9 inhibitors or inducers, a dosage adjustment may be warranted

Fuente:  FDA  y  ANMAT

 

 

 

Para más información puede acceder a los sitios oficiales del ANMAT | FDA

 

 

 
 

 

 

Dirección: Urquiza 3100, Rosario (2000), Santa Fe, Argentina
e-mail: contactohepagastro@gmail.com
TEL: 0341-4393511

Diseño web IDEAS MED | Tabone Juan Pablo | www.ideasmed.com.ar |

Hepagastro | Dr. Federico Tanno | Todos los derechos reservados 2015.-